TURNING POINT THERAPEUTICS I's ticker is TPTX and the CUSIP is 90041T108. A total of 213 filers reported holding TURNING POINT THERAPEUTICS I in Q2 2022. The put-call ratio across all filers is 3.08 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $22,140,000 | +1199.3% | 294,218 | +363.6% | 0.01% | – |
| Q1 2022 | $1,704,000 | -84.1% | 63,460 | -71.8% | 0.00% | – |
| Q4 2021 | $10,726,000 | +269.6% | 224,840 | +414.7% | 0.00% | – |
| Q3 2021 | $2,902,000 | -41.0% | 43,686 | -30.7% | 0.00% | – |
| Q2 2021 | $4,918,000 | +14.6% | 63,040 | +38.9% | 0.00% | – |
| Q1 2021 | $4,292,000 | -63.4% | 45,369 | -52.9% | 0.00% | -100.0% |
| Q4 2020 | $11,728,000 | +190.9% | 96,244 | +108.5% | 0.00% | – |
| Q3 2020 | $4,032,000 | +254.3% | 46,152 | +161.9% | 0.00% | – |
| Q2 2020 | $1,138,000 | -79.0% | 17,625 | -85.5% | 0.00% | -100.0% |
| Q1 2020 | $5,421,000 | +684.5% | 121,405 | +994.2% | 0.00% | – |
| Q4 2019 | $691,000 | +62.6% | 11,095 | -1.8% | 0.00% | – |
| Q3 2019 | $425,000 | – | 11,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 708,233 | $44,116,000 | 18.91% |
| Corriente Advisors, LLC | 285,000 | $17,753,000 | 9.54% |
| Cormorant Asset Management, LP | 3,396,650 | $211,577,000 | 8.44% |
| Opaleye Management Inc. | 340,500 | $21,210,000 | 4.16% |
| Orbimed Advisors | 2,745,327 | $171,006,000 | 2.44% |
| Parkman Healthcare Partners LLC | 101,434 | $6,318,000 | 1.82% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 35,000 | $2,179,000 | 0.78% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 366,000 | $22,798,000 | 0.73% |
| Artal Group S.A. | 300,000 | $18,687,000 | 0.72% |
| DAFNA Capital Management LLC | 30,408 | $1,894,000 | 0.65% |